The requirement applies to all GLP-1 receptor agonist medications, including semaglutide products such as Ozempic and Wegovy, as well as tirzepatide products Mounjaro and Zepbound. (AFP pic)LOS ANGELES: The US Food and Drug Administration (FDA) on Monday required manufacturers of all glucagon-like peptide-1 (GLP-1) receptor agonist medications to update their safety labelling, reported Xinhua.
The changes must include information about a potentially increased risk of a rare but serious eye condition that can cause permanent vision loss.
In a drug safety communication issued on Monday, the FDA alerted patients and healthcare professionals to a potential increased risk of non-arteritic anterior ischaemic optic neuropathy (Naion) associated with the use of GLP-1 receptor agonist medications.
